A detailed history of Douglass Winthrop Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Douglass Winthrop Advisors, LLC holds 942 shares of VRTX stock, worth $472,620. This represents 0.01% of its overall portfolio holdings.

Number of Shares
942
Previous 937 0.53%
Holding current value
$472,620
Previous $391,000 12.79%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

BUY
$392.81 - $485.53 $1,964 - $2,427
5 Added 0.53%
942 $441,000
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $6,425 - $6,886
19 Added 2.07%
937 $325,000
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $162,495 - $205,127
918 New
918 $202,000
Q1 2021

May 13, 2021

SELL
$207.02 - $241.31 $197,497 - $230,209
-954 Closed
0 $0
Q4 2020

Jan 27, 2021

SELL
$207.01 - $276.09 $44,507 - $59,359
-215 Reduced 18.39%
954 $225,000
Q3 2020

Nov 12, 2020

SELL
$255.65 - $303.1 $51,130 - $60,620
-200 Reduced 14.61%
1,169 $318,000
Q2 2020

Jul 17, 2020

SELL
$225.48 - $295.8 $16,685 - $21,889
-74 Reduced 5.13%
1,369 $397,000
Q1 2020

Apr 23, 2020

SELL
$199.77 - $247.81 $20,176 - $25,028
-101 Reduced 6.54%
1,443 $343,000
Q2 2019

Jul 10, 2019

SELL
$164.61 - $190.37 $254,157 - $293,931
-1,544 Closed
0 $0
Q4 2018

Jan 16, 2019

SELL
$151.91 - $192.21 $16,102 - $20,374
-106 Reduced 6.42%
1,544 $256,000
Q3 2018

Oct 12, 2018

SELL
$167.73 - $192.74 $33,546 - $38,548
-200 Reduced 10.81%
1,650 $318,000
Q2 2018

Jul 24, 2018

SELL
$145.72 - $169.96 $38,615 - $45,039
-265 Reduced 12.53%
1,850 $314,000
Q1 2018

May 08, 2018

SELL
$151.6 - $177.13 $1,364 - $1,594
-9 Reduced 0.42%
2,115 $345,000
Q3 2017

Nov 13, 2017

BUY
$148.13 - $162.24 $314,628 - $344,597
2,124
2,124 $0

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Douglass Winthrop Advisors, LLC Portfolio

Follow Douglass Winthrop Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Douglass Winthrop Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Douglass Winthrop Advisors, LLC with notifications on news.